EP. 1: Introduction and Exploring the Financial Burden of Follicular Lymphoma
Watch
EP. 2: Optimizing First- and Second-Line Treatment Strategies in Follicular Lymphoma
EP. 3: Advancing Care in Relapsed/Refractory Follicular Lymphoma Beyond Chemotherapy
Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and reduce chemotherapy toxicity.
EP. 4: Integrating Bispecific Antibodies and Evolving Strategies in Relapsed/Refractory Follicular Lymphoma
Explore the advancements in bispecific antibodies for follicular lymphoma, addressing treatment options, toxicities, and unmet patient needs in cancer care.
EP. 5: Implications of the RELEVANCE Study and Optimal Use of R² in Second-Line Follicular Lymphoma
Explore the latest insights on second-line therapies for follicular lymphoma, including the benefits and challenges of R2 treatment.
EP. 6: Targeted Therapies and Bispecific Antibodies in Second-Line Follicular Lymphoma
Explore the promising role of Epcoritamab and bispecific therapies in second-line treatment for follicular lymphoma, enhancing patient outcomes.
EP. 7: Epcoritamab Maintenance and Quality of Life Considerations in Follicular Lymphoma
EP. 8: Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma
A recent ASH study highlights the impact of CAR T and bispecific therapies on patient time commitment and quality of life in treatment decisions.
EP. 9: Operational Challenges and Solutions for Implementing Bispecific Antibodies in Follicular Lymphoma
Explore the operational challenges and solutions in administering bispecific therapies for follicular lymphoma, focusing on patient safety and education.
